Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Omacor capsules
0212000ABBBAAAA
|
Omacor | Omega-3-acid ethyl esters | Cardiovascular System | 13,929 |
|
Eicosapentaenoic acid 460mg/Docosahexaenoic acid 380mg caps
0212000ABAAAAAA
|
Omega-3-acid ethyl esters | Omega-3-acid ethyl esters | Cardiovascular System | 8,303 |
|
Teromeg 1000mg capsules
0212000ABBCAAAA
|
Teromeg | Omega-3-acid ethyl esters | Cardiovascular System | 323 |
|
Omega 3-acid-ethyl esters 1000mg capsules
0212000ABBEAAAA
|
Omega-3-Acid Ethyl Esters (Glenmark) | Omega-3-acid ethyl esters | Cardiovascular System | 209 |
|
Omega 3-acid-ethyl esters 1000mg capsules (strides)
0212000ABBLAAAA
|
Omega-3-acid-ethyl esters (Strides) | Omega-3-acid ethyl esters | Cardiovascular System | 103 |
|
Prestylon 1g capsules
0212000ABBDAAAA
|
Prestylon | Omega-3-acid ethyl esters | Cardiovascular System | 15 |
|
AceOmeg 1000mg capsules
0212000ABBJAAAA
|
AceOmeg | Omega-3-acid ethyl esters | Cardiovascular System | 1 |
|
Dualtis 1000mg capsules
0212000ABBHAAAA
|
Dualtis | Omega-3-acid ethyl esters | Cardiovascular System | 1 |
|
G & G Omega 3 1000mg softgels capsules
0212000ABBIAAAA
|
G & G Omega 3 | Omega-3-acid ethyl esters | Cardiovascular System | 1 |
|
A1 Omega 1000mg capsules
0212000ABBKAAAA
|
A1 Omega | Omega-3-acid ethyl esters | Cardiovascular System | No data available |
|
Nebbaro 1000mg capsules
0212000ABBFAAAA
|
Nebbaro | Omega-3-acid ethyl esters | Cardiovascular System | No data available |
|
Omega 3 1000mg capsules
0212000ABBGAAAA
|
Omega 3 | Omega-3-acid ethyl esters | Cardiovascular System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.